“SURPRISE SWITCHEROO” | Industry Legal Challenge to FDA Denial Orders | RegWatch
The fight to save vaping in the United States appeared almost over when FDA issued Marketing Denial Orders to over 300 vaping product manufacturers, thus requiring more than 5-million vaping products to be taken off the market. But dozens of vape companies fought back, launching legal action against FDA.
Today on RegWatch, hear from Eric Heyer, partner at the law firm Thompson Hine and litigator behind many of the court challenges on behalf of major U.S. vape manufacturers. Learn why several vape companies have been granted judicial stays on their Marketing Denial Orders, which means these producers can continue to sell their vape products while lawsuits remain active.
Could the industry stave off disaster? Find out.
Only on RegWatch by RegulatorWatch.com
Released: February 17, 2022
Produced by Brent Stafford
This episode is supported by DEMAND VAPE
*Support RegWatch - Go to https://support.regulatorwatch.com
-
36:31
RegWatch
1 year agoHIJACKED | FDA Approval Process in Shambles | RegWatch
5 -
4:22
MLordandGod
1 year agoDoctor Calls Out CDC, FDA – Warns They Are Deliberately ‘Breaking the Law’
30 -
4:39
Theusmilitarynews.com
10 months ago5th Circuit Court of Appeals Revives Doctors Claim FDA Overstepped Its Authority on Ivermectin
206 -
4:38
Restored Republic
10 months ago5th Circuit Court of Appeals Revives Doctors Claim FDA Overstepped Its Authority on Ivermectin
3.25K -
31:46
Moses Lake Professional Pharmacy
10 months agoEP 388 Dr. Mary Talley Bowden: An Update on Suing the FDA
5353 -
7:38
ArmedAttorneys
9 months ago $0.03 earnedBruen Application in Federal Switchblade Act Lawsuit
4561 -
8:13
Eric Deters Media
2 years ago $0.10 earnedDBL Law. Frauds
2054 -
44:23
RegWatch
6 months agoBLISTERING DECISION | Fifth Circuit Court Rebukes FDA’s PMTA Process | RegWatch (Live)
8 -
5:50
SmokeyHardwick
10 months agoFederal Court Rules FDA Abused Its Authority with Anti-Ivermectin Messaging to Americans
13 -
21:46
RegWatch
3 years agoE353 - COMPLY OR DIE | SFATA RELEASES PROGRAM TO EASE FDA REPORTING BURDEN | REGWATCH
10